Drug Profile
Serplulimab - Shanghai Henlius Biotech
Alternative Names: Anti-PD-1 monoclonal antibody - Shanghai Henlius Biotech; Anti-PD-I mAb - Shanghai Henlius Biotech; Han Si Zhuang; HANSIZHUANG; HLX-10; Recombinant humanized anti-PD-1 monoclonal antibody - Shanghai Henlius Biotech; ZerpidioLatest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator Henlix Biotech
- Developer Henlix Biotech; PT Kalbe Genexine Biologics; Shanghai Henlius Biotech
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours
- Phase III Gastric cancer
- Phase II/III Colorectal cancer
- Phase II Cervical cancer; Hepatitis B; Liver cancer; Nasopharyngeal cancer; Squamous cell cancer
- Preclinical Lymphoma
Most Recent Events
- 13 Mar 2024 Serplulimab receives Innovation Passport designation through the Innovative Licensing and Access Pathway (ILAP) in UK
- 31 Jan 2024 Shanghai Henlius Biotech completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) (IV) in China (NCT05400265)
- 25 Jan 2024 Launched for Small cell lung cancer in Indonesia (IV)